KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.80

Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.

Neal D Shore, Felipe Cruz, Luke Nordquist, Laurence Belkoff, William J Aronson, Bhupendra Tolia, Arnold Cinman, Roohollah Sharifi, Jorge Ortiz, Jacqueline Parkin, Shankar Srinivasan, Toni Sarapohja, Matthew R Smith

Future Oncol 18(40) 4473-4482

PMID36753353
PMCID-
DOI10.2217/fon-2022-0943
发表日期2023-02-08
入排依据:The record describes a subgroup analysis of a Phase III randomized trial (ARAMIS) with drug intervention and time-to-event endpoints, but it is not the original primary result report of the trial. It is a secondary analysis focusing on a specific patient population, thus excluded per criteria.
摘要

摘要

Aim: Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the phase III ARAMIS study. We evaluated outcomes in Black/African-American patients in ARAMIS. Materials & methods: Patients with nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide (n = 955) or placebo (n = 554) plus androgen-deprivation therapy. The primary end point was MFS. Secondary end points included OS and safety. Results: In 52 (3.4%) Black/African-American patients, darolutamide improved MFS (median: not reached vs 12.4 months) and OS (3-year survival rates: 100 vs 71%) versus placebo. The safety profile of darolutamide in Black/African-American patients was consistent with that of all ARAMIS patients. Conclusion: In Black/African-American patients, darolutamide improved MFS and OS and was well tolerated, consistent with the overall ARAMIS population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。